Suppr超能文献

食物、一种抗酸剂以及H2拮抗剂雷尼替丁对口服直接Xa因子抑制剂BAY 59-7939(利伐沙班)在健康受试者体内吸收的影响。

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

作者信息

Kubitza Dagmar, Becka Michael, Zuehlsdorf Michael, Mueck Wolfgang

机构信息

Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany.

出版信息

J Clin Pharmacol. 2006 May;46(5):549-58. doi: 10.1177/0091270006286904.

Abstract

To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two 5-mg tablets (fasted and fed), four 5-mg tablets (fasted), or one 20-mg tablet (fasted and fed). In 2 drug interaction studies, BAY 59-7939 (six 5-mg tablets) was given alone or with ranitidine (150 mg twice daily, preceded by a 3-day pretreatment phase) or antacid (10 mL). Plasma samples were obtained to assess pharmacokinetic and pharmacodynamic parameters of BAY 59-7939. In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939. Compared with baseline, BAY 59-7939 resulted in a relative increase in maximum prothrombin time (PT) prolongation of 44% (10 mg) and 53% (20 mg) in the fasted state, compared with 53% and 83% after food. Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type. No significant difference in C(max) and AUC was observed with coadministration of BAY 59-7939 and ranitidine or antacid.

摘要

为研究食物以及抗酸剂(铝镁氢氧化物)或雷尼替丁的使用对BAY 59-7939(利伐沙班)吸收的影响,在健康男性受试者中进行了4项随机研究。在2项食物相互作用研究中,受试者分别服用两片5毫克的BAY 59-7939片剂(空腹和进食状态)、四片5毫克的BAY 59-7939片剂(空腹)或一片20毫克的BAY 59-7939片剂(空腹和进食状态)。在2项药物相互作用研究中,单独给予BAY 59-7939(六片5毫克片剂)或与雷尼替丁(每日两次,每次150毫克,给药前有3天的预处理阶段)或抗酸剂(10毫升)联合使用。采集血浆样本以评估BAY 59-7939的药代动力学和药效学参数。在有食物存在的情况下,达峰时间(t(max))延迟1.25小时;最大浓度(C(max))和曲线下面积(AUC)增加,在较高剂量的BAY 59-7939时个体间变异性降低。与基线相比,BAY 59-7939在空腹状态下使最大凝血酶原时间(PT)延长相对增加44%(10毫克)和53%(20毫克),进食后则为53%和83%。进食后最大PT延长时间延迟0.5至1.5小时,食物类型对此无相关影响。BAY 59-7939与雷尼替丁或抗酸剂联合使用时,未观察到C(max)和AUC有显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验